Perrigo (NYSE:PRGO) Shares Gap Up After Better-Than-Expected Earnings

Posted by George Bondi on Aug 5th, 2026

Perrigo Company plc (NYSE:PRGO – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $10.78, but opened at $12.62. Perrigo shares last traded at $13.19, with a volume of 1,348,316 shares traded.

The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.16. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the company earned ($0.06) EPS. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 9.0%. The ex-dividend date of this dividend is Friday, August 28th. Perrigo’s payout ratio is -8.85%.

Analyst Ratings Changes

A number of brokerages have issued reports on PRGO. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Perrigo presently has an average rating of “Hold” and a consensus price target of $19.33.

Read Our Latest Stock Analysis on PRGO

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. raised its stake in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. Kestra Investment Management LLC grew its stake in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after acquiring an additional 1,213 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new position in shares of Perrigo in the 4th quarter valued at about $28,000. 95.91% of the stock is owned by hedge funds and other institutional investors.

Perrigo Trading Up 20.0%

The company has a 50-day moving average of $10.52 and a 200 day moving average of $11.56. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The company has a market cap of $1.79 billion, a PE ratio of -0.99, a price-to-earnings-growth ratio of 1.28 and a beta of 0.51.

About Perrigo

(Get Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.